MSMengchi Sun

Mengchi Sun

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Mengchi Sun has a total of 90 co-authors. Here are the top co-authors by number of shared publications:

  • Jin Sun

    Shenyang Pharmaceutical University

    10 shared publications
  • Zhonggui He

    Wuya College of Innovation Shenyang Pharmaceutical University 110016 Shenyang China

    8 shared publications
  • Jin Sun

    Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, Liaoning, China; Joint International Research Laboratory of Intelligent Drug Delivery Systems, Ministry of Education, China

    5 shared publications
  • Xianbao Shi

    Department of Pharmacy, The First Affiliated Hospital of Jinzhou Medical University, Jinzhou, Liaoning 121000, China

    5 shared publications
  • Funan Liu

    Department of Surgical Oncology and General Surgery, The First Hospital of China Medical University, Shenyang, China

    3 shared publications
  • Lihang Qu

    The 4th People's Hospital of Shenyang China Medical University Shenyang Liaoning 110031 China

    3 shared publications

Latest Publications

  • Open Access

    Invasive pulmonary fungal diseases: Towards formulation-optimized targeted therapeutic strategies

    by Lei Pan, Xu Zhang, Bowen Yang, Zhonggui He, Mengchi Sun, Jin Sun, Wei Wang

    Invasive pulmonary fungal diseases (IPFD) represent a growing global health crisis, with escalating incidence and mortality rates, posing a particularly life-threatening risk to immunocompromised populations. The complexity of diagnosis, limited therapeutic options, and the growing challenge of antifungal resistance have significantly constrained the clinical efficacy, leading to poor patient outcomes. Recently, the integration of revolutionary drug delivery platforms with classical antifungal agents, such as optimized nebulized amphotericin B, voriconazole-loaded liposomes and inhalable amphotericin B microspheres, has demonstrated significant clinical potential, particularly in pulmonary applications, by markedly enhancing biodistribution at the infection site while substantially minimizing systemic adverse effects. This comprehensive review synthesized recent advances in IPFD research, encompassing epidemiological characteristics, molecular pathogenesis, clinical manifestations, cutting-edge diagnostic technologies (including advanced imaging, fungal-specific biomarkers and molecular techniques like polymerase chain reaction (PCR) and next-generation sequencing) as well as formulation-based therapeutics that optimize pulmonary targeting to improve efficacy and reduce systemic toxicity. This review aimed to provide insights for the future development of precision-targeted delivery mechanisms and next-generation antifungal agents.


  • Open Access

    An inhalable microbe-oncolytic virus consortium for lung cancer treatment

    by Hao Ling, Shihua Yang, Xianbao Shi, Zhenguo Cheng, Wei Wang, Meng Niu, Funan Liu, Jin Sun, Mengchi Sun


  • Turning Foe into Friend: Bridging Neutrophil Biological Characteristics and Neutrophil‐Based Oncolytic Nanotherapeutics

    by Sitong Chen, Tao Zhang, Lihang Qu, Shuwen Han, Mengchi Sun, Xi Yang

    Neutrophils, the primary responders to inflammation in infection and cancer, exhibit precise chemotaxis to target sites. They also show functional plasticity in tumor progression, with distinct subsets exerting opposing effects—either fostering oncogenesis or mediating antitumor responses. Recently, the introduction of nanotherapeutics offers the opportunity to effectively augment the anti‐tumor effects of neutrophils and avoid the risk of tumor promotion during treatment. In this review, oncopromotion (cell proliferation, angiogenesis, immunodepression, and DNA injury), a combination of oncogenesis and promotion, and metastasis (transmigration and pre‐niche) conditions are used to summarize the tumorigenic effect of neutrophils. Regarding the tumor suppression mechanism of neutrophils, three “C” stages are further generalized that is, coordination, cytolysis, and chemosecretion. Neutrophils coordinate innate and adaptive immunity via cytokines and surface molecules, mediate antibody‐dependent cytotoxicity to disrupt cancer cell membranes, and secrete inflammatory factors to modulate ion channels and directly kill tumor cells. Capitalizing on neutrophils' chemotaxis and nanotherapeutic interactions, membrane encapsulation and whole‐cell mediation nanoplatforms are integrated to synthesize cutting‐edge advancements in neutrophil nanomedicines, particularly, multimechanistic anticancer strategies. Last but not least, an outlook for introducing AI aimed at improving the safety, scalability, and reproducibility of neutrophil‐based oncolytic nanotherapeutics is provided.

  • Open Access

    In Situ Sustained Delivery of Tumor Cell‐Derived Extracellular Nanovesicles With Oncolytic Adenoviruses for Potentiating Cancer Immunotherapy

    by Tianye Wang, Sheng Zhao, Zao Ji, Zhonggui He, Zhenguo Cheng, Zhen Gu, Yuqi Zhang, Jin Sun, Funan Liu, Mengchi Sun

    Oncolytic adenoviruses (OVs) can directly eliminate cancer cells and subsequently activate immune responses, exhibiting potent antitumor therapeutics. However, it was observed that the immune cells can also be lysed during viral treatment, evidently dampening the OVs‐mediated antitumor immune response. In this study, we develop a microneedle (MN)‐based in situ tumor cell‐derived extracellular nanovesicle (TDEV)‐cloaked OVs platform to enhance cancer immunotherapy and reduce immune cell exhaustion. In this platform, tumor cells pre‐infected with OVs are loaded into the upper reservoir of the MN device. Following the transdermal administration, the hollow MN would constantly facilitate the transport of in situ the generated TDEV‐encapsulating OVs into the tumor site for sustained delivery of OVs, which could subsequently infect cancer cells selectively rather than immune cells. Enhanced antigens triggered by improved intratumoral OVs killing can be presented by non‐exhausted dendritic cells, further evoking significant immunotherapeutic effects in both TC‐1‐hCD46 xenograft tumor‐bearing mice and postoperative tumor recurrence mice models.


  • Open Access

    Regulation of tumor hypoxic microenvironment by cyanobacteria-photosensitizer hybrid bioplatform for enhanced photodynamic therapy

    by Mengchi Sun, Xu Wang, Hongmei Wang, Chengwu Tang, Jingwen Bai

    Tumor hypoxic microenvironments limit the generation efficiency of reactive oxygen species (ROS) in photodynamic therapy (PDT) and exacerbate immune suppression, severely restricting its clinical efficacy. To overcome this bottleneck, this study developed a bio-organic hybrid delivery system based on oxygen-producing cyanobacteria and nano-photosensitizers (PCC7942@ICG-NPs), which synergistically enhances efficacy through in situ oxygen delivery and augment ROS. Specifically, indocyanine green (ICG) was loaded onto bovine serum albumin (BSA) via hydrophobic interactions to form stable nanoparticles (ICG-NPs), and the positively charged surface of the nanoparticles enabled efficient self-assembly with the oxygen-producing cyanobacterium PCC7942 by electrostatic interactions. Upon near-infrared laser activation, the cyanobacteria continuously release molecular oxygen through photosynthesis, significantly increasing the local tumor oxygen partial pressure (pO₂), which potentiates ICG-mediated photodynamic therapeutic efficacy and boosts ROS production, simultaneously improving the tumor hypoxic microenvironment and triggering systemic antitumor immunity. This work provides an innovative strategy to overcome tumor hypoxia and combined PDT therapy, showing significant clinical translation potential.


  • Microorganism delivery of cancer vaccines

    by Fei Han, Linzhou Yin, Lihang Qu, Shuwen Han, Mengchi Sun, Yang Xi


  • Open Access

    Sonodynamic biomimetic-nanomedicine fight cancers

    by Anni Zhang, Xu Zheng, Guangqi Yan, Xiaoqi Liu, DongXuan Xie, Xiaohe Xu, Mengchi Sun, Zhijun Liu

    Sonodynamic therapy (SDT) represents an innovative oncological treatment modality that harnesses the synergistic effects of low-intensity ultrasound and sonosensitizers to kill tumor cells. However, this dynamic therapeutic strategy faces multiple obstacles, including physicochemical barriers in the tumor microenvironment (TME) and the potential toxicity of off-target sonosensitizers, which may accumulate in off-target sites and be non-specifically activated by ultrasound, leading to damage of normal tissues. Recently, biomimetic-nanomedicine platforms, specifically designed to target the TME challenges, have emerged as a potent solution, enabling the development of SDT that enhance therapeutic outcomes, which even derives the concept of the sonodynamic biomimetic-nanomedicine (SBNM). In light of the states, we herein aim to summarize a cutting-edge review on the rapid advances of SBNM. Firstly, tumor-killing mechanisms and development and classification of sonosensitizers are outlined. In addition, recent progresses in various biomimetic-nanomedicines, containing red blood cell membrane-coated, immune cell membrane-coated, cancer cell membrane-coated, hybrid membrane-coated, exosomal and microbial mimicking, are described in the development of preclinical research. Importantly, we offer an in-depth presentation for the superiority of SBNM designed to address physicochemical barriers of TME and abnormalization of the anti-tumor immunity. Last but not least, the challenges and perspectives related to SBNM are also discussed.


  • Top Cited Papers
    Open Access

    Nanomedicines as disruptors or inhibitors of biofilms: Opportunities in addressing antimicrobial resistance

    by Jiaming Lan, Jingyu Zou, He Xin, Jin Sun, Tao Han, Mengchi Sun, Meng Niu


  • Open Access

    Approaches and applications in transdermal and transpulmonary gene drug delivery

    by Anni Zhang, Xuran Zhang, Jiahui Chen, Xianbao Shi, Xijuan Yu, Zhonggui He, Jin Sun, Mengchi Sun, Zhijun Liu

    Gene therapy has emerged as a pivotal component in the treatment of diverse genetic and acquired human diseases. However, effective gene delivery remains a formidable challenge to overcome. The presence of degrading enzymes, acidic pH conditions, and the gastrointestinal mucus layer pose significant barriers for genetic therapy, necessitating exploration of alternative therapeutic options. In recent years, transdermal and transpulmonary gene delivery modalities offer promising avenues with multiple advantages, such as non-invasion, avoided liver first-pass effect and improved patient compliance. Considering the rapid development of gene therapeutics via transdermal and transpulmonary administration, here we aim to summarize the nearest advances in transdermal and transpulmonary gene drug delivery. In this review, we firstly elaborate on current delivery carrier in gene therapy. We, further, describe approaches and applications for enhancing transdermal and transpulmonary gene delivery encompassing microneedles, chemical enhancers, physical methods for transdermal administration as well as nebulized formulations, dry powder formulations, and pressurized metered dose formulations for efficient transpulmonary delivery. Last but not least, the opportunities and outlooks of gene therapy through both administrated routes are highlighted.